[{"id":"1356603e-b2dd-488c-b74a-f432af18b9a1","acronym":"DDRiver Solid Tumours 301","url":"https://clinicaltrials.gov/study/NCT04170153","created_at":"2021-06-11T21:52:37.231Z","updated_at":"2025-02-25T12:27:22.944Z","phase":"Phase 1","brief_title":"Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","source_id_and_acronym":"NCT04170153 - DDRiver Solid Tumours 301","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • tuvusertib (M1774)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-24"},{"id":"a7bc76a3-7767-4569-b28f-313c198056ba","acronym":"MAGNITUDE","url":"https://clinicaltrials.gov/study/NCT03748641","created_at":"2021-01-18T18:22:54.153Z","updated_at":"2025-02-25T13:52:43.687Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03748641 - MAGNITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 765","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2025-02-20"},{"id":"3b6e3d94-f722-44f3-897f-bf1317cea5d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672095","created_at":"2023-01-05T14:58:27.769Z","updated_at":"2025-02-25T14:09:21.750Z","phase":"Phase 1/2","brief_title":"Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT05672095","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA wild-type","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/18/2025","start_date":" 04/18/2025","primary_txt":" Primary completion: 11/27/2026","primary_completion_date":" 11/27/2026","study_txt":" Completion: 11/27/2026","study_completion_date":" 11/27/2026","last_update_posted":"2025-02-18"},{"id":"ab61b8a8-7577-42c8-aace-25d2ec073ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700721","created_at":"2023-01-26T15:02:55.768Z","updated_at":"2025-02-25T14:09:25.231Z","phase":"Phase 2","brief_title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","source_id_and_acronym":"NCT05700721","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 08/07/2025","primary_completion_date":" 08/07/2025","study_txt":" Completion: 08/07/2027","study_completion_date":" 08/07/2027","last_update_posted":"2025-02-17"},{"id":"6335c6b4-3622-4c19-8459-665aa604c082","acronym":"OVNI-B","url":"https://clinicaltrials.gov/study/NCT06827353","created_at":"2025-02-25T14:45:06.368Z","updated_at":"2025-02-25T14:45:06.368Z","phase":"","brief_title":"Niraparib Versus Bevacizumab As Maintenance Therapy in Patients with De Novo Ovarian Cancer Without Homologous Recombination Deficiency","source_id_and_acronym":"NCT06827353 - OVNI-B","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-14"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"cedde79c-686f-4afe-89d0-1fd3a8d96cf4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05200260","created_at":"2022-01-20T14:53:41.699Z","updated_at":"2025-02-25T14:38:18.943Z","phase":"Phase 2","brief_title":"Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","source_id_and_acronym":"NCT05200260","lead_sponsor":"Shanghai Gynecologic Oncology Group","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • docetaxel • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"85201425-83fc-431f-9c04-0410092876c4","acronym":"TBCRC 050","url":"https://clinicaltrials.gov/study/NCT03368729","created_at":"2021-01-18T16:37:35.798Z","updated_at":"2025-02-25T13:12:32.252Z","phase":"Phase 1/2","brief_title":"Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT03368729 - TBCRC 050","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive • EGFR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-04"},{"id":"da831d56-b69a-4333-9086-5a3e811681fc","acronym":"AMPLITUDE","url":"https://clinicaltrials.gov/study/NCT04497844","created_at":"2021-01-18T21:32:59.167Z","updated_at":"2025-02-25T17:00:35.684Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","source_id_and_acronym":"NCT04497844 - AMPLITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 696","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 01/07/2025","primary_completion_date":" 01/07/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-03"},{"id":"27645473-7a93-4f67-8b27-cef657563cbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05021562","created_at":"2021-08-25T14:53:28.046Z","updated_at":"2025-02-25T17:30:52.775Z","phase":"","brief_title":"A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice","source_id_and_acronym":"NCT05021562","lead_sponsor":"Takeda","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-01-30"},{"id":"4d0aa8dd-1906-440f-bdc4-7b7bd07db44b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076513","created_at":"2021-10-13T16:58:18.037Z","updated_at":"2025-02-25T13:12:47.827Z","phase":"Phase 1","brief_title":"Trial of Niraparib in Participants with Newly-diagnosed Glioblastoma and Recurrent Glioma","source_id_and_acronym":"NCT05076513","lead_sponsor":"Nader Sanai","biomarkers":" IDH1 • IDH2 • ATRX","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-23"},{"id":"db660b09-0f52-4a82-9f38-79007e8d5211","acronym":"MORPHEUS mUC","url":"https://clinicaltrials.gov/study/NCT03869190","created_at":"2021-01-18T19:04:50.965Z","updated_at":"2025-02-25T13:18:52.965Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","source_id_and_acronym":"NCT03869190 - MORPHEUS mUC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 05/21/2026","study_completion_date":" 05/21/2026","last_update_posted":"2025-01-03"},{"id":"532394c5-f790-470a-8ca5-552f40205b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694715","created_at":"2023-01-23T14:59:41.946Z","updated_at":"2025-02-25T13:13:14.067Z","phase":"Phase 1","brief_title":"Combination Therapy in Cancers With Mutations in DNA Repair Genes","source_id_and_acronym":"NCT05694715","lead_sponsor":"University of California, San Francisco","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-12-18"},{"id":"04a57d4f-2959-452c-80a6-f0212d657b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04992013","created_at":"2021-08-05T13:53:09.751Z","updated_at":"2025-02-25T13:12:43.122Z","phase":"Phase 2","brief_title":"Niraparib in Tumors Metastatic to the CNS","source_id_and_acronym":"NCT04992013","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3","pipe":" | ","alterations":" HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/05/2022","start_date":" 04/05/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"15daf957-b2c4-4980-8a9a-08eb0a5becce","acronym":"RAISE","url":"https://clinicaltrials.gov/study/NCT05718323","created_at":"2023-02-08T17:00:18.337Z","updated_at":"2025-02-25T13:13:15.274Z","phase":"Phase 2","brief_title":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","source_id_and_acronym":"NCT05718323 - RAISE","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" SLFN11","pipe":" | ","alterations":" SLFN11 expression • SLFN11 overexpression","tags":["SLFN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SLFN11 expression • SLFN11 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-12-12"},{"id":"28c1fd40-f94e-4cca-b4b5-626fe1cac96a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04673448","created_at":"2021-01-19T20:45:05.881Z","updated_at":"2025-02-25T13:19:47.405Z","phase":"Phase 1","brief_title":"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04673448","lead_sponsor":"University of Washington","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-11-08"},{"id":"0274e43f-cc0c-414e-9481-44dc1368c6ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515575","created_at":"2022-09-08T14:56:05.365Z","updated_at":"2025-02-25T13:13:08.083Z","phase":"Phase 2","brief_title":"A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA","source_id_and_acronym":"NCT05515575","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-05"},{"id":"36a397ed-0e68-47a2-95c4-59ca2210321e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03601923","created_at":"2021-01-18T17:42:32.758Z","updated_at":"2025-02-25T13:18:35.093Z","phase":"Phase 2","brief_title":"Niraparib in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT03601923","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CHEK2 mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CHEK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/22/2018","start_date":" 08/22/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-10-22"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"27e444fa-8027-41ef-911b-992a53105e03","acronym":"","url":"https://clinicaltrials.gov/study/NCT04481113","created_at":"2021-01-18T21:31:29.345Z","updated_at":"2025-02-25T13:19:27.891Z","phase":"Phase 1","brief_title":"Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04481113","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 10/11/2023","primary_completion_date":" 10/11/2023","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-17"},{"id":"1056dca4-95a8-462c-8bb1-1287b2e57c22","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161493","created_at":"2023-12-08T17:16:39.097Z","updated_at":"2025-02-25T13:13:32.183Z","phase":"Phase 1","brief_title":"ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors","source_id_and_acronym":"NCT06161493","lead_sponsor":"Haider Mahdi","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • ZEN-3694"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-10-11"},{"id":"154083c9-cc5f-4216-821f-b8dde20dd216","acronym":"","url":"https://clinicaltrials.gov/study/NCT03945721","created_at":"2021-01-18T19:25:37.802Z","updated_at":"2025-02-25T13:18:58.299Z","phase":"Phase 1","brief_title":"A Phase I Study of Niraparib Administered Concurrently with Postoperative RT in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT03945721","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-09-23"},{"id":"e073adbc-974d-423b-b408-1f0614b44b3b","acronym":"TBCRC 056","url":"https://clinicaltrials.gov/study/NCT04584255","created_at":"2021-01-18T21:52:19.886Z","updated_at":"2025-02-25T13:19:39.281Z","phase":"Phase 2","brief_title":"Niraparib + Dostarlimab in BRCA Mutated Breast Cancer","source_id_and_acronym":"NCT04584255 - TBCRC 056","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2029","study_completion_date":" 07/17/2029","last_update_posted":"2024-09-19"},{"id":"acd4fa6f-57f1-4f7a-8049-516c634a95f7","acronym":"PARPi-PANC","url":"https://clinicaltrials.gov/study/NCT05442749","created_at":"2022-07-05T14:54:24.995Z","updated_at":"2025-02-25T13:13:04.354Z","phase":"Phase 2","brief_title":"Niraparib As First Line Therapy with Metastatic Homologous Repair-deficient Pancreatic Cancer","source_id_and_acronym":"NCT05442749 - PARPi-PANC","lead_sponsor":"Centre Leon Berard","biomarkers":" BRCA1 • BRCA2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • FANCD2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • FANCD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 09/15/2026","study_completion_date":" 09/15/2026","last_update_posted":"2024-09-11"}]